INSYS Therapeutics, Cannabinoids Technology, Initiated a Phase 2 Clinical Trial

Recently, INSYS Therapeutics, Inc. INSY , a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently initiated a Phase 2 clinical trial of its cannabidiol (CBD) oral solution for evaluation of safety and efficacy in pediatric patients with Prader-Willi syndrome, a rare genetic disease characterized by insatiable appetite in children that often leads to obesity, type 2 diabetes and premature death.

“Individuals with Prader-Willi syndrome face relentless hunger, which requires strict environmental controls, such as locking pantries and refrigerators to prevent life-threatening obesity,” explained Theresa Strong, director of research programs at the Foundation for Prader-Willi Research, whose PWS Awareness Month is May. “Currently there are no treatments for the most challenging aspects of the disorder, which takes a toll on patients’ families as well.”

Prader-Willi syndrome is the most common genetic cause of obesity that has been identified, affecting upwards of 400,000 people worldwide, according to epidemiological

... read more at: http://chasingmarkets.com/news/15b07118f348ef/INSYS_Therapeutics%2C_Cannabinoids_Technology%2C_Initiated_a_Phase_2_Clinical_Trial